72
Participants
Start Date
April 20, 2016
Primary Completion Date
June 15, 2022
Study Completion Date
August 20, 2027
Acalabrutinib in combination with BR
Acalabrutinib in combination with VR
Research Site, Lake Success
Research Site, Nashville
Research Site, Bologna
Research Site, Louisville
Research Site, Columbus
Research Site, Ann Arbor
Research Site, Houston
Research Site, Seattle
Research Site, Seattle
Research Site, Hackensack
Research Site, Morristown
Research Site, Krakow
Research Site, Lodz
Research Site, Olsztyn
Research Site, Warsaw
Lead Sponsor
Collaborators (1)
AstraZeneca
INDUSTRY
Acerta Pharma BV
INDUSTRY